These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27077548)

  • 1. Pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia successfully treated with sildenafil.
    Miyake R; Fujino T; Abe K; Hosokawa K; Ohtani K; Morisaki H; Yamada O; Higo T; Ide T
    Int J Cardiol; 2016 Jul; 214():275-6. PubMed ID: 27077548
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.
    Yokokawa T; Sugimoto K; Kimishima Y; Misaka T; Yoshihisa A; Morisaki H; Yamada O; Nakazato K; Ishida T; Takeishi Y
    Intern Med; 2020 Jan; 59(2):221-227. PubMed ID: 31511490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report.
    Walsh LJ; Collins C; Ibrahim H; Kerins DM; Brady AP; O Connor TM
    J Med Case Rep; 2022 Mar; 16(1):99. PubMed ID: 35232468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.
    Alsheikh B; Aljohani O; Coufal NG
    Cardiol Young; 2018 Dec; 28(12):1475-1476. PubMed ID: 30303062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
    Eyries M; Coulet F; Girerd B; Montani D; Humbert M; Lacombe P; Chinet T; Gouya L; Roume J; Axford MM; Pearson CE; Soubrier F
    Clin Genet; 2012 Aug; 82(2):173-9. PubMed ID: 21651515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined treatment of sildenafil and inhaled iloprost in pediatric patients with severe pulmonary arterial hypertension].
    Santos-Martínez LE; Jiménez-Santos M; Arenas-Fonseca JG; Moreno-González A; Medina-Concebida LE
    Arch Cardiol Mex; 2015; 85(1):80-4. PubMed ID: 25576259
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
    Trembath RC; Thomson JR; Machado RD; Morgan NV; Atkinson C; Winship I; Simonneau G; Galie N; Loyd JE; Humbert M; Nichols WC; Morrell NW; Berg J; Manes A; McGaughran J; Pauciulo M; Wheeler L
    N Engl J Med; 2001 Aug; 345(5):325-34. PubMed ID: 11484689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
    Dardi F; Manes A; Palazzini M; Bachetti C; Mazzanti G; Rinaldi A; Albini A; Gotti E; Monti E; Bacchi Reggiani ML; Galiè N
    Eur Respir J; 2015 Aug; 46(2):414-21. PubMed ID: 26022952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association therapy with macitentan added to sildenafil in a thalassemic patient with pulmonary hypertension.
    Correale M; Zicchino S; Monaco I; Brunetti ND; Di Biase M
    Int J Cardiol; 2016 Oct; 220():80-1. PubMed ID: 27389438
    [No Abstract]   [Full Text] [Related]  

  • 10. Altitude-induced pulmonary hypertension on one-day rapid ascent of Mount Fuji: incidence and therapeutic effects of sildenafil.
    Bhattachar S; Sikri G; Thapa B
    Echocardiography; 2016 Sep; 33(9):1441. PubMed ID: 27677646
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
    Girerd B; Montani D; Coulet F; Sztrymf B; Yaici A; Jaïs X; Tregouet D; Reis A; Drouin-Garraud V; Fraisse A; Sitbon O; O'Callaghan DS; Simonneau G; Soubrier F; Humbert M
    Am J Respir Crit Care Med; 2010 Apr; 181(8):851-61. PubMed ID: 20056902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
    Vachiery JL; Rubin LJ
    Eur Respir J; 2015 Aug; 46(2):297-8. PubMed ID: 26232474
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genetic analysis of a family affected with pulmonary hypertension secondary to hereditary hemorrhagic telangiectasia].
    Du X; Wang Y; Ye Q
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2018 Apr; 35(2):197-201. PubMed ID: 29652991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mutations of ACVRL1 gene in a pedigree with hereditary hemorrhagic telangiectasia].
    Luo JW; Chen H; Yang LQ; Zhu AL; Wu YA; Li JW
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Jun; 25(3):308-10. PubMed ID: 18543223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel use of sildenafil in the management of pulmonary hypertension due to post-catheter ablation 'stiff left atrial syndrome'.
    Wong GR; Lau DH; Baillie TJ; Middeldorp ME; Steele PM; Sanders P
    Int J Cardiol; 2015 Feb; 181():55-6. PubMed ID: 25482279
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulmonary arterial hypertension as the first manifestation in a patient with hereditary hemorrhagic telangiectasia.
    Ishiwata T; Terada J; Tanabe N; Abe M; Sugiura T; Tsushima K; Tada Y; Sakao S; Kasahara Y; Nakanishi N; Morisaki H; Tatsumi K
    Intern Med; 2014; 53(20):2359-63. PubMed ID: 25318803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of multiple ACVRL1 mutations in patients with pulmonary arterial hypertension by targeted exome capture.
    Piao C; Zhu Y; Zhang C; Xi X; Liu X; Zheng S; Li X; Guo J; Jia L; Nakanishi T; Cai T; Gu H; Du J
    Clin Sci (Lond); 2016 Sep; 130(17):1559-69. PubMed ID: 27316748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary arterial hypertension and portal hypertension in a patient with hereditary hemorrhagic telangiectasia.
    Pousada G; Baloira A; Valverde D
    Med Clin (Barc); 2015 Mar; 144(6):261-4. PubMed ID: 25543221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
    McLaughlin V; Channick RN; Ghofrani HA; Lemarié JC; Naeije R; Packer M; Souza R; Tapson VF; Tolson J; Al Hiti H; Meyer G; Hoeper MM
    Eur Respir J; 2015 Aug; 46(2):405-13. PubMed ID: 26113687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension.
    Beck-Broichsitter M; Hecker A; Kosanovic D; Schmehl T; Gessler T; Weissmann N; Ghofrani HA; Kissel T; Seeger W; Schermuly RT
    Nanomedicine; 2016 Jan; 12(1):63-8. PubMed ID: 26393885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.